All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
During the 25th Congress of the European Hematology Association (EHA), the AML Hub spoke to Lars Bullinger, Charité – Universitätsmedizin Berlin, Berlin, DE. We asked: Have big data changed the view on AML risk classification?
In recent years, the prognostic value of molecular markers has been established, with six already incorporated into the European LeukemiaNet guidelines. This recent compilation of datasets across Europe has provided additional prognostic information and promises to better assist treatment decisions and improve patient outcomes.
Have big data changed the view on AML risk classification?
Approaches and emerging therapies for TP53 AML
TP53-mutant AML is an area of unmet need, demonstrating high interpatient heterogeneity. In this podcast with Naval Daver, he describes the efforts being made to establish TP53 as a therapeutic target,...
ESH 2019 | How do genomic and epigenomic alterations synergize in AML?
Lars Bullinger explains that epigenetic mutations often predispose to leukemic events.
Subscribe to get the best content related to AML delivered to your inbox